Disopyramide: six years' experience.
Since its approval by the FDA six years ago, oral disopyramide has earned a recognized role in the treatment of ventricular arrhythmias. During this time, clinical experience has refined our knowledge of this agent, allowing revision of dosing guidelines and better selection of patients. This review explores the recent therapeutic experience with disopyramide.
D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004206:Disopyramide / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D004311:Double-Blind Method; D006801:Humans; D010276:Parasympatholytics / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology*; D011897:Random Allocation; D014693:Ventricular Fibrillation / Q000188:drug therapy
D010276:Parasympatholytics; D011725:Pyridines; D004206:Disopyramide